|
|
 Previous Article | Table of Contents | Next Article 
2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-
cell lymphoma
A Saven, CJ Carrera, DA Carson, E Beutler and LD Piro
Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA 92037.
Cutaneous T-cell lymphomas are disfiguring malignant lymphoproliferative
disorders for which standard therapy has been principally palliative.
2-Chlorodeoxyadenosine (2-CdA), a new purine analogue resistant to
degradation by adenosine deaminase that has substantial activity against
lymphoid neoplasms, was administered to 16 patients with cutaneous
involvement by T-cell lymphoma. All patients had failed topical treatment
modalities and/or systemic therapies. Fifteen patients were evaluable; one
patient was not evaluable due to incomplete therapy and follow-up. The
overall response rate was 47%. Three of 15 patients (20%) achieved complete
responses and four of 15 patients (27%) achieved partial responses. The
median duration of response was 5 months. One patient remains in
unmaintained complete remission at 52+ months. Therapy was well tolerated.
Myelosuppression was the principal toxicity encountered, occurring in 8 of
15 (53%) patients. 2-CdA is an effective new agent for the treatment of
cutaneous T-cell lymphoma and warrants further study both as a single agent
and in combination regimens.
Volume 80,
Issue 3,
pp. 587-592,
08/01/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Egeler, B. E. Favara, M. van Meurs, J. D. Laman, and E. Claassen
Differential In Situ Cytokine Profiles of Langerhans-Like Cells and T Cells in Langerhans Cell Histiocytosis: Abundant Expression of Cytokines Relevant to Disease and Treatment
Blood,
December 15, 1999;
94(12):
4195 - 4201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven and L. Piro
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia
N. Engl. J. Med.,
March 10, 1994;
330(10):
691 - 697.
[Full Text]
|
|
|
|
|
